Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study
Open Access
- 5 February 2018
- journal article
- research article
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 17 (1) , 25
Abstract
Little is known about sex gap in the management and outcomes of dyslipidemia among diabetics in the Arabian Gulf. The aim if this study was to determine sex differences in the management and outcomes of dyslipidemia in diabetic patients in the Arabian Gulf. This study was derived from the Centralized Pan-Middle-East Survey on the management of hypercholesterolemia. Patients recruited were aged ≥18 years on lipid lowering drugs for ≥3 months (stable medication for ≥6 weeks). Outcomes were based on the joint Consensus Statement of the American Diabetes Association and American College of Cardiology Foundation. Analyses were performed using univariate and multivariate logistic regression techniques. The mean age of the cohort (n = 3336) was 57 ± 11 years and 45% (n = 1486) were females. Females were less likely to be on rosuvastatin (7.6% vs 12%; P < 0.001), atorvastatin (41% vs 46%; P = 0.005) and combination hypolipidemic therapy (5.6% vs 2.8%; P < 0.001) but more likely to be on simvastatin (51% vs 39%; P < 0.001) than males. Females, especially those with very high atherosclerotic cardiovascular disease (ASCVD) risk status, were also less likely to achieve LDL-cholesterol [adjusted odds ratio (aOR), 0.58; 95% confidence interval (CI): 0.40–0.86; P = 0.006], non-HDL-cholesterol [aOR, 0.68; 95% CI: 0.46–0.99; P = 0.048] and apolipoprotein B [aOR, 0.64; 95% CI: 0.44–0.92; P = 0.016] lipid targets. Diabetic women were less likely to be on optimal hypolipemic therapy and consequently less likely to attain lipid goals compared to men. This shows a sex gap on dyslipidemia treatment in the region. Diabetic women with very high ASCVD risk status need to be aggressively treated to lower their risk of cardiovascular events.Keywords
Funding Information
- AstraZeneca
This publication has 29 references indexed in Scilit:
- Centralized Pan-Middle East Survey on the Undertreatment of HypercholesterolemiaAngiology, 2013
- Impact of Diabetes on Cardiovascular Disease: An UpdateInternational Journal of Hypertension, 2013
- Prevalences of overweight, obesity, hyperglycaemia, hypertension and dyslipidaemia in the Gulf: systematic reviewJRSM Short Reports, 2011
- Clinical Implications of Pharmacogenetic Variation on the Effects of StatinsDrug Safety, 2011
- Gender differences in the implementation of cardiovascular prevention measures after an acute coronary eventHeart, 2010
- The Gender Differences in Baseline Characteristics and Statin Intervention Among Outpatients with Coronary Heart Disease in China: The China Cholesterol Education ProgramClinical Cardiology, 2009
- Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national surveyAmerican Heart Journal, 2006
- Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: metaanalysis of randomised controlled trialsBMJ, 2006
- Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studiesBMJ, 2005
- National Study of Physician Awareness and Adherence to Cardiovascular Disease Prevention GuidelinesCirculation, 2005